In conclusion, image fusion of PSMA PET/CT and MRI using clinical software is currently accessible, accurate (within clinically acceptable range), and can aid the visualisation of prostate cancer for use in diagnosis and management. This evidence concerns the gene FOLH1 and prostate carcinoma.